Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $2.2 million.

  • Fate Therapeutics' Capital Expenditures rose 34505.05% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year increase of 49766.3%. This contributed to the annual value of $730000.0 for FY2024, which is 8813.59% down from last year.
  • As of Q3 2025, Fate Therapeutics' Capital Expenditures stood at $2.2 million, which was up 34505.05% from $1.4 million recorded in Q2 2025.
  • Fate Therapeutics' 5-year Capital Expenditures high stood at $18.4 million for Q4 2021, and its period low was $51000.0 during Q2 2024.
  • Its 5-year average for Capital Expenditures is $5.2 million, with a median of $2.2 million in 2025.
  • In the last 5 years, Fate Therapeutics' Capital Expenditures plummeted by 9768.08% in 2024 and then surged by 257058.82% in 2025.
  • Quarter analysis of 5 years shows Fate Therapeutics' Capital Expenditures stood at $18.4 million in 2021, then tumbled by 63.65% to $6.7 million in 2022, then tumbled by 97.29% to $181000.0 in 2023, then plummeted by 45.86% to $98000.0 in 2024, then surged by 2147.96% to $2.2 million in 2025.
  • Its Capital Expenditures was $2.2 million in Q3 2025, compared to $1.4 million in Q2 2025 and $1.2 million in Q1 2025.